Research & development

Biopharmaceuticals

Ludger's biopharmaceutical R&D is aimed at understanding the structure-function of biopharmaceuticals in terms of glycosylation, improving drug development by changing glycosylation to increase safety and efficacy, and implementing Quality by Design glycoprofiling workflows to maximise monitoring efficiency.

Collaborative projects

NanoCarb
2018–2022

NanoCarb – Glyco-Nanoparticles for Applications in Advanced Nanomedicine

NanoCarb (a Marie Curie European Training Network H2020-funded project) is a multidisciplinary consortium of universities, research centres and SMEs spanning nanotechnology, carbohydrate chemistry, glycobiology and in vitro/in vivo screening. The network develops novel, well-characterised nanomaterials with synthetic and native glycans for therapeutics and new drug delivery applications, training early stage researchers at the interface of nanotechnology and glycoscience.

The project was awarded €4.2 million and ran for four years from October 2018, coordinated by Dr Marco Monopoli, Department of Chemistry, Royal College of Surgeons in Ireland, recruiting 15 Early Stage Researchers. Ludger led the training package for the project.

www.nanocarb.eu →

A4B
2017–2021

A4B – Analytics for Biologics

An EU Horizon 2020 research and innovation programme (Marie Skłodowska-Curie grant agreement No 765502): a research training network on qualitative and quantitative analysis and purification of therapeutic proteins.

This pan-European consortium focuses on the qualitative and quantitative analysis and purification of therapeutic proteins. A PhD student (ESR) based at Ludger for three years worked on automatable, high-throughput techniques to determine site specificity and quantification of N- and O-glycan profiles of EPO and TNF-AB, building on VTAG (used to analyse and relatively quantify glycan types on the Fc receptor of monoclonal antibodies without releasing the glycan).

www.analytics4biologics.eu →

Glycoenzymes for Bioindustries
2015–2020

Glycoenzymes for Bioindustries

Glycoenzymes are responsible for the biosynthesis of all glycans and glycoconjugates, providing a rich source of biocatalysts for industrial applications, though few are commercially available. This project generated a panel of glycoenzymes for glycoscience and industrial biotechnology applications — around 1,000 different enzymes produced along with a comprehensive database of benchmarked performance data, with selected examples produced at industrial specification for evaluation by industrial partners.

Funded by Innovate UK, BBSRC and EPSRC, with a consortium comprising the University of Manchester, John Innes Centre, University of Newcastle, Institute of Food Research, Ludger Ltd (industrial partner), Biocatalysis Ltd (industrial partner), and Prozomix Ltd (sub-contractor).

www.glycoenzymes.com →

King's College London / IBCarb
Jan–Sept 2017

GlycoShape: Defining and Designing Altered IgE Glycoforms

Academic supervisors: Dr Gerd Wagner & Dr Sophia Karagiannis (King's College London). Industrial partner: Ludger Ltd.

Immunoglobulin E (IgE)-based antibodies are under investigation as novel immunotherapeutics for cancer treatment. IgE is a heavily glycosylated glycoprotein whose glycans make up more than 10% of its molecular mass, offering a unique opportunity to alter the biological properties of IgE-based antibodies by manipulating glycan structure. GlycoShape brought together expertise in IgE pharmacology, chemical inhibitors of glycan biosynthesis and high-performance glycoanalytics to provide proof-of-concept for a cost-effective, flexible method for glycoengineering recombinant therapeutic glycoproteins.

High Glycan
2011–2016

HIGH GLYCAN

An EU FP7-funded programme for development of high-throughput glycomics technology. Dysfunctional glycosylation is associated with a wide range of diseases including cancer, diabetes, and congenital, cardiovascular, immunological and infectious disorders, and glycosylation of biopharmaceuticals can impact safety and therapeutic efficacy. HighGlycan addressed the lack of high-throughput analytical methods able to reliably quantify glycan structures in complex biological samples, using HPLC, MS and CGE-LIF technologies.

GlycoStore
2014–2016

GlycoStore – a Database of Retention Properties for Glycan Analysis

A curated chromatographic, electrophoretic and mass-spectrometry composition database of N-, O- and glycosphingolipid (GSL) glycans and free oligosaccharides, built on datasets from GlycoBase (Oxford Glycobiology Institute and NIBRT) and extended with data from BTI A*STAR, Macquarie University and Ludger Ltd. GlycoStore provides access to around 850 unique glycan structure entries supported by over 8,500 retention positions from HILIC U/HPLC, PGC chromatography with ESI-MS/MS, and CE-LIF.

Zhao S, Walsh I, Abrahams JL, Royle L, Nguyen-Khuong T, Spencer D, Fernandes DL, Packer NH, Rudd PM, Campbell MP. Bioinformatics. 2018 Sep 15;34(18):3231-3232. doi: 10.1093/bioinformatics/bty319 →

University of Sheffield BBSRC
2015–2019

UK BBSRC iCASE award – PhD student, University of Sheffield

University of Reading BBSRC
2013–2017

UK BBSRC iCASE award – PhD student, University of Reading

To view our posters, please visit our Posters page.

Interested in collaborating?

Talk to us about a research partnership.

Contact us